Skip to main content

ANAPTYSBIO, INC

For the period ended Dec 31, 2025. Filed Mar 3, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 3, 2026

ANAB$47.97+3.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Power of Attorney

Each person whose individual signature appears below hereby authorizes and appoints Daniel Faga and Eric Loumeau, and each of them, with full power of substitution and re-substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Daniel FagaPresident, Chief Executive Officer and Director
Daniel Faga(Principal Executive Officer)March 3, 2026
/s/ Dennis MulroyChief Financial Officer
Dennis Mulroy(Principal Accounting and Financial Officer)March 3, 2026
/s/ Dennis FentonDirectorMarch 3, 2026
Dennis Fenton, Ph.D.
/s/ Rita JainDirectorMarch 3, 2026
Rita Jain, M.D
/s/ Magda MarquetDirectorMarch 3, 2026
Magda Marquet, Ph.D.
/s/ Oleg NodelmanDirectorMarch 3, 2026
Oleg Nodelman
/s/John OrwinDirectorMarch 3, 2026
John Orwin
/s/ Hollings RentonDirectorMarch 3, 2026
Hollings Renton
/s/ John SchmidDirectorMarch 3, 2026
John Schmid
/s/ J. Anthony WareDirectorMarch 3, 2026
J. Anthony Ware, M.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.